Identification of candidate biomarker MRPL23 and its prognostic potential in non-small cell lung cancer with emphasis on the squamous cell carcinoma subtype

MRPL23 overexpression, particularly in lung squamous cell carcinoma, is associated with poor prognosis and may serve as an independent prognostic factor in NSCLC. These results suggest that MRPL23 represents a promising biomarker for improving risk stratification and guiding personalized therapeutic strategies in patients with NSCLC.